Abstract
Undoubtedly, individuals with systemic lupus erythematosus (SLE) are at higher risk for developing cerebrovascular disease than counterparts from the general population without SLE. In a metaanalysis of studies from around the world, the likelihood of individuals with SLE developing both ischemic and hemorrhagic stroke (intracerebral and/or subarachnoid hemorrhage) was more than 2 times that of the general population1. Risks for stroke appear to be highest soon after SLE diagnosis, and concomitant antiphospholipid syndrome (APS) in these patients does not markedly exacerbate risks for ischemic stroke2.